Short-term amiodarone treatment attenuates the production of monocyte cytokines and chemokines by C-reactive protein and improves cardiac function in patients with idiopathic dilated cardiomyopathy and ventricular tachycardia

Circulation Journal

Volumn 73, Issue 4, 2009, Pages 639-646

  Hirasawa, Yasuhiro ^a   Nakagomi, Akihiro ^a   Kobayashi, Yoshinori ^a   Katoh, Takao ^a   Mizuno, Kyoichi ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Antiarrhythmia agents; Cardiomyopathy; Heart failure; Tachyarrhythmias

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HEART VENTRICLE TACHYCARDIA; HUMAN; HUMAN CELL; LOADING DRUG DOSE; MALE; OPTIMAL DRUG DOSE; PERIPHERAL BLOOD MONONUCLEAR CELL; PREVALENCE; PROTEIN BLOOD LEVEL; SHORT COURSE THERAPY;

AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; C-REACTIVE PROTEIN; CARDIOMYOPATHY, DILATED; CELLS, CULTURED; CHEMOKINE CCL2; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; RECOVERY OF FUNCTION; STROKE VOLUME; TACHYCARDIA, VENTRICULAR; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 65649089012     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-08-0794     Document Type: Article

References (32)

1. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 1994; 344: 493-498.
2. Singh SN, Fletcher RD, Fisher SG, Sighn SG, Sighn BN, Lewis HD, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia: Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995; 333: 77-82.
3. Aukrust P, Ueland T, Muller F, Andereassen AK, Nordoy I, Aas H, et al. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 1998; 97: 1136-1143. (Pubitemid 28152886)
4. Damås JK, Gullestad L, Ueland T, Solum NO, Simonsen S, Frøland SS, et al. CXC-chemokines, a new group of cytokines in congestive heart failure: Possible role of platelets and monocytes. Cardiovasc Res 2000; 45: 428-436. (Pubitemid 30069508)
5. Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S, et al. C-reactive protein in heart failure: Prognostic value and the effects of valsartan. Circulation 2005; 112: 1428-1434. (Pubitemid 41291768)
6. Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 1992; 4: 361-368.
7. Nishio Y, Sato Y, Taniguchi R, Shizuta S, Doi T, Morimoto T, et al. Cardiac troponin T vs other markers in patients with congestive heart failure. Circ J 2007; 71: 631-635. (Pubitemid 46683349)
8. Mortensen RF, Zhong W. Regulation of phagocytic leukocyte activities by C-reactive protein. J Leukocyte Biol 2000; 67: 495-500.
9. Murray DR, Freeman GL. Proinflammatory cytokines: Predictors of a failing heart? Circulation 2003; 107: 1460-1462. (Pubitemid 36378479)
10. Petersen JW, Felker GM. Inflammatory biomarkers in heart failure. Congest Heart Fail 2006; 12: 324-328.
11. Volanakis JE. Human C-reactive protein: Expression, structure, and function. Mol Immunol 2001; 38: 189-197. (Pubitemid 32786776)
12. Xue C, Feng Y, Wo J, Li Y. Prognostic value of high-sensitivity C-reactive protein in patients with chronic heart failure. NZ Med J 2006; 119: U2314.
13. Matsumori A, Ono K, Nishio R, Nose Y, Sasayama S. Amiodarone inhibits production of tumor necrosis factor-alpha by human mononuclear cells: A possible mechanism for its effect in heart failure. Circulation 1997; 96: 1386-1389. (Pubitemid 27375326)
14. Nakagomi A, Freedman SB, Geczy CL. Interferon-γ and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: Relationship with age, sex, and hormone replacement treatment. Circulation 2000; 101: 1785-1791. (Pubitemid 30213099)
15. Herre JM, Sauve MJ, Malone P, Griffin JC, Helmy I, Langberg JJ, et al. Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol 1989; 13: 442-449. (Pubitemid 19055672)
16. Hohnloser SH, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects: A review with special reference to torsade de pointes tachycardia. Ann Intern Med 1994; 121: 529-535.
17. Singh BN, Ahmed R. Class III antiarrhythmic drugs. Curr Opin Cardiol 1994; 9: 12-22. (Pubitemid 24012178)
18. Singh BN. Choice and chance in drug therapy of cardiac arrhythmias: Technique versus drug-specific responses in evaluation of efficacy. Am J Cardiol 1993; 72: 114F-124F. (Pubitemid 23360766)
19. Komatsu T, Tachibana H, Sato Y, Ozawa M, Nakamura M, Okumura K. Efficacy of amiodarone for preventing the recurrence of symptomatic paroxysmal and persistent atrial fibrillation after cardioversion. Circ J 2007; 71: 46-51. (Pubitemid 46045549)
20. Aiba T, Kurita T, Taguchi A, Shimizu W, Suyama K, Aihara N, et al. Long-term efficacy of empirical chronic amiodarone therapy in patients with sustained ventricular tachyarrhythmia and structural heart disease. Circ J 2002; 66: 367-371. (Pubitemid 34462390)
21. Parissis JT, Filippatos G, Nikolaou V, Adamopoulos S. Cytokines and anti-cytokine therapeutic approaches to chronic heart failure. Eur J Intern Med 2002; 13: 356-364. (Pubitemid 35291946)
22. Behr TM, Wang X, Aiyar N, Coatney RW, Li X, Koster P, et al. Monocyte chemoattractant protein-1 is upregulated in rats with volume-overloaded congestive heart failure. Circulation 2000; 102: 1315-1322.
23. Kubota T, McTierman CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 1997; 81: 627-635.
24. Kolattukudy PE, Quach T, Bergese S, Breckenridge S, Hensley J, Altschuld R, et al. Myocarditis induced by targeted expression of the MCP-1 gene in murine cardiac muscle. Am J Pathol 1998; 152: 101-111. (Pubitemid 28028051)
25. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury. Part I: Basic mechanisms and in vivo monitoring of ROS. Circulation 2003; 108: 1912-1916. (Pubitemid 37296532)
26. Boyle EM Jr, Kovacich JC, Hebert CA, Canty TG Jr, Chi E, Morgan EN, et al. Inhibition of interleukin-8 blocks myocardial ischemia-reperfusion injury. J Thorac Cardiovas Surg 1998; 116: 114-121. (Pubitemid 28328635)
27. Wang CH, Li SH, Weisel RD, Fedak PWM, Dumont AS, Szmitko P, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003; 107: 1783-1790. (Pubitemid 36418360)
28. Ito H, Ono K, Nishio R, Sasayama S, Matsumori A. Amiodarone inhibits interleukin 6 production and attenuates myocardial injury induced by viral myocarditis in mice. Cytokine 2002; 17: 197-202.
29. Tachikawa H, Kodama M, Watanabe K, Takahashi T, Ma M, Kashimura T, et al. Amiodarone improves cardiac sympathetic nerve function to hold norepinephrine in the heart, prevents left ventricular remodeling, and improves cardiac function in rat dilated cardiomyopathy. Circulation 2005; 111: 894-899. (Pubitemid 40279891)
30. Nakajima K, Yamazaki K, Yamada E, Kanaji Y, Kosaka S, Sato K, et al. Amiodarone stimulates interleukin-6 production in cultured human thyrocytes, exerting cytotoxic effects on thyroid follicles in suspension culture. Thyroid 2001; 11: 101-109. (Pubitemid 32221032)
31. Oral H, Fisher SG, Fay WP, Singh SN, Fletcher RD, Morady F. Effects of amiodarone on tumor necrosis factor-alpha levels in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999; 83: 388-391. (Pubitemid 29066499)
32. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT, for the ATTACH Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial. Circulation 2003; 107: 3133-3140. (Pubitemid 36793081)